Search for a trial | Research with human participants

1 results

Phase 1/2 dose escalation and expansion study evaluating MCLA-129, a human anti-EGFR and anti-c-MET bispecific antibody, in patients with advanced NSCLC and other solid tumors

Approved WMORecruiting

This study has been transitioned to CTIS with ID 2024-514461-19-00 check the CTIS register for the current data. Phase 1 - Primary Objective• To determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of single-agent MCLA-…